306
Views
19
CrossRef citations to date
0
Altmetric
Articles

Physicians' Perspectives and Practice Patterns Toward Opportunistic Salpingectomy in High- and Low-Risk Women

, , , , , , & show all
Pages 51-61 | Received 20 Jun 2016, Accepted 27 Sep 2016, Published online: 28 Dec 2016

References

  • Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34(3):433–443.
  • Erickson BK, Conner MG, Landen CN, Jr. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol 2013;209(5):409–414.
  • Morse AN, Hammer RA, Walter AJ, Baker S, Magtibay PM. Does hysterectomy without adnexectomy in patients with prior tubal interruption increase the risk of subsequent hydrosalpinx? Am J Obstet Gynecol 2002;187(6):1483–5; Discussion 1485–1486.
  • Piacenza JM, Salsano F. Post-hysterectomy fallopian tube prolapse. Eur J Obstet Gynecol Reprod Biol 98(2):253–255.
  • Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013;105(11):812–822.
  • Hermsen BB, Olivier RI, Verjeijen RH, van Beurden M, de Hullu JA, Massuger LF, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007;96(9):1335–1342.
  • Stirling D, Evans DG, Pichert G, Shenton A, Kirk EN, Rimmer S, et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics System. J Clin Oncol 2005;23(24):5588–5596.
  • Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch TH, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304(9):967–975.
  • Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Cancer Netw 2010;8(5):562–594.
  • Finch APM, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32(15):1547–1553.
  • Daly MB, Dresher CW, Yates MS, Jeter JM, Karlan BY, Alberts SD, et al. Salpingectomy as a means to reduce ovarian cancer risk. Cancer Prev Res 2015;8(5):342–348.
  • Kwon JS, Tinger A, Pansegrau G, McAlpine J, Housty M, McCullum M, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol 2013;121(1):14–24.
  • Mack WJ, Slater CC, Xiang M, Shoupe D, Lobo RA, Hodis HN. Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertil Steril 2004;82(2):391–397.
  • Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 2009;113(5):1027–1037.
  • Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncol 2012;13(4):385–394.
  • Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kown JS, Lee CH, et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012;10(5):296–306.
  • Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer 2011;21(5):846–851.
  • Patrono MG, Iniesta MD, Malpica A, Lu KH, Fernandez RO, Salvo G, et al. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review. Gynecol Oncol 2015;139(3):568–572.
  • Gilks CB, Iriving J, Kobel M, Lee C, Singh N, Wilkinson N, et al. Incidental non-uterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas. Am J Surg Pathol 2015;39(3):357–364.
  • Morrison JC, Blanco LZ Jr., Vang R, Ronnett BM. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series. Am J Surg Pathol 2015;39(4):442–453.
  • Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993;270(23):2813–2818.
  • Rice MS, Hankinson SE, Tworoger SS. Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the Nurses' Health Studies. Fertil Steril 2014;102(1):192–198, e3.
  • McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton DM, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014;210(5):471, e1–e11.
  • Dar P, Sachs D, Strassburger D, Bukovsky I, Arieli S. Ovarian function before and after salpingectomy in artificial reproductive technology patients. Hum Reprod 2000;15(1):142–4.
  • Sezik M, Ozkaya O, Demir F, Sezik HT, Kaya H. Total salpingectomy during abdominal hysterectomy: effects on ovarian reserve and ovarian stromal blood flow. J Obstet Gynaecol Res 2007;33(6):863–869.
  • Clinical Practice Committee, Society of Gynecologic Oncology. SGO Clinical Practice Statement: Salpingectomy for ovarian cancer prevention. Chicago: Society of Gynecologic Oncology; 2013. Available from: https://www.sgo.org/clinical-practice/guidelines/sgo-clinical-practice-statement-salpingectomy-for-ovarian-cancer-prevention/. [Accessed 2016 Jun 10]
  • Committee on Gynecologic Practice, The American College of Obstetricians and Gynecologists. Committee Opinion No. 620: Salpingectomy for ovarian cancer prevention. Obstet Gynecol 2015;125(1):279–281.
  • Morosky CM, Kueck KD. Physician opinions regarding elective bilateral salpingectomywith hysterectomy and for sterilization. Obstet Gynecol 2014;123(Supp):126s.
  • Gill SE, Mills BB. Physician opinions regarding elective bilateral salpingectomy with hysterectomy and for sterilization.J Minim Invasive Gynecol 2013;20(4):517–521.
  • Manchanda R, Menon U. Opportunistic bilateral salpingectomy (OBS) for the prevention of ovarian cancer should be offered in the context of a clinical trial FOR: there is lack of clarity on a number of key issues. BJOG 2016;123(3):463.
  • Kapurubandara S, Qin V, Gurram D, Anpalagan A, Merkur H, Hogg R, et al. Opportunistic bilateral salpingectomy during gynaecological surgery for benign disease: A survey of current Australian practice. Aust N Z J Obstet Gynaecol 2015;55(6):606–611.
  • Kamran MW, Vaughan D, Crosby D, Wahab NA, Saadeh FA, Gleeson N. Opportunistic and interventional salpingectomy in women at risk: a strategy for preventing pelvic serous cancer (PSC). Eur J Obstet Gynecol Reprod Biol 2013;170:251–254.
  • McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014;210: 471,e1-11.
  • Chene G, de Rochambeau B, Le Bail-Carval K, Beaufils E, Chabert P, Mellier G, et al. Current surgical practice of prophylactic and opportunistic salpingectomy in France. Gynecol Obstet Fertil 2016;44(7–8):377–384.
  • Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101(2):80–87.
  • Arnold AG, Kauff ND. Prophylactic oophorectomy may differentially reduce breast cancer risk in women with BRCA1 versus BRCA2 mutations. Curr Breast Cancer Rep 2009;1(3):157–161.
  • Banet N, Kurman RJ. Two types of ovarian cortical inclusion cysts: proposed origin and possible role in ovarian serous carcinogenesis. Int J Gynecol Pathol 2015;34(1):3–8.
  • Pearce CL, et al. Population distribution of lifetime risk of ovarian cancer in the United States. Cancer Epidemiol Biomarkers Prev 2015;24(4):671–676.
  • Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MD, Wendl MC, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun 2014;5:3156.
  • Wright JD, Silver RM, Bonanno C, Gaddipati S, Lu YS, Simpson LL, et al. Practice patterns and knowledge of obstetricians and gynecologists regarding placenta accreta. J Matern Fetal Neonatal Med 2013;26(16):1602–1609.
  • Wright JD, Raglan GB, Schulkin J, Fialkow MF. Attitudes and beliefs regarding the utility of robotically assisted gynecologic surgery among practicing gynecologists. J Health Care Qual 2015. [Epub ahead of print]
  • Raglan GB, Margolis B, Paulus RA, Schulkin J. Electronic health record adoption among obstetrician/gynecologists in the United States: Physician practices and satisfaction. J Health Care Qual 2015. [Epub ahead of print]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.